Stay in touch with the NIAID SBIR/STTR Team
NIAID encourages applications in the areas of HIV/AIDS prevention and treatment. The mission of Division of AIDS (DAIDS) is to help ensure an end to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV); supporting the development of therapies for HIV infection and its complications and co-infections; and supporting the development of vaccines and other prevention strategies.
Below are areas of interests from DAIDS. The subject matter expert is available to answer questions and advise on the application process.
If you do not see your HIV/AIDS-related topic here, the application may not be prioritized but will still be reviewed. Contact Daniella Livnat (NED) or Natalia Kruchinin (NED) if you have any questions about your application and don’t see an appropriate subject matter expert below.
Preclinical development and evaluation of HIV vaccines, adjuvants, and delivery systems in animal models using SIV, SHIV, or HIV.
Vaccines that enhance innate and mucosal immunities and induce broadly reactive and long lasting neutralizing antibodies are program priorities.
Novel technologies (e.g., nanotechnology) and vaccine vectors are also priority areas of research interest.
Yen LiPreclinical Research and Development Branchyli@niaid.nih.gov301-496-3816
Development of anti-HIV agents directed at new viral or cellular targets.
Brigitte SandersTargeted Interventions Branchsandersbe@niaid.nih.gov301-496-6714
Development of novel anti-HIV drugs and therapeutics with focus on technological aspects such as multiplex analysis of drugs and innovative, streamlined methods for drug screening and drug delivery (e.g., multifunctional therapeutics based on nanotechnology).
Development of bio-assay and bio-imaging applications for the assessment of HIV pathogenesis.
Kailash GuptaTargeted Interventions Branchkgupta@niaid.nih.gov301-435-3724
Preclinical development of single and combination non-vaccine biomedical prevention candidates (topical microbicides, PrEP and multipurpose prevention technologies (MPT)) which prevent the transmission of HIV in the genital and gastrointestinal tracts of men and women.
Development of oral, injectable, implantable, and topical sustained delivery strategies for topical microbicides, PrEP, and MPT.
Creation and advancement of new technologies, targets, and approaches, including nanotechnology, which promote the safety, efficacy, adherence, and acceptability of non-vaccine biomedical prevention candidates and strategies.
Jim A. TurpinPreclinical Microbicide and Prevention Research Branchjturpin@niaid.nih.gov301-451-2732
Development, standardization, validation, and evaluation of improved technologies to detect HIV, to evaluate immune responses to HIV vaccines and to vaccine vectors, or to correlate immune responses associated with vaccine efficacy.
Thandi OnamiVaccine Clinical Research Branchthandi.email@example.com
Development and evaluation of practical and affordable tests to measure viral load, CD4+ cell counts, drug toxicities, and drug resistance to monitor populations in resource-poor settings.
Development of tests to detect early infection in seropositive HIV-infected individuals.
Michael UsseryDrug Development and Clinical Sciences Branchmussery@niaid.nih.gov301-402-0134
Development of novel, non-sputum-based methods for the diagnosis of active and latent TB infection in HIV-positive or HIV-negative infants and children.
Marco SchitoContractor, Henry M. Jackson Foundationschitom@niaid.nih.gov301-594-5374
Preclinical discovery and development of antimicrobial agents directed against Mycobacterium avium, Pneumocystis pneumonia, and Cryptococcus neoformans (and other pathogenic fungi).
Development and delivery of nanotechnology-based therapeutics to target pathogen or pathogen-infected cells.
Influence of antiretrovirals (e.g., ritonavir) on antimicrobial efficacy.
Chris LambrosComplications and Coinfections Research Branchcl29r@nih.gov 301-435-3769
Preclinical development and evaluation of therapeutic vaccines and other immune-based therapies to attenuate HIV disease progression or reduce HIV infectiousness.
Tony ConleyTargeted Interventions Branchconleyto@niaid.nih.gov301-451-2739
Development of gene therapies for HIV.
Frosso VoulgaropoulouTargeted Interventions Branchfrossov@mail.nih.gov301-451-2704
Research to assess and overcome specific biomedical obstacles in HIV vaccine discovery, especially by application of novel technology to vaccine discovery and/or by the development and supply of novel reagents and other resources useful in novel vaccine discovery.
Stuart ShapiroPreclinical Research and Development Branchsshapiro@niaid.nih.gov301-402-0122
Discovery and development of agents or strategies for pre-exposure prophylaxis (PrEP) (single or multiple agents, immunological, pharmacological, or other potential approaches directed against viral and/or host targets). Development of pharmacological tools to examine PK/PD in fluids and tissue, new formulation and delivery systems (including nanotechnology-based approaches) for coitally-dissociated use, and optimization of animal models for screening of candidate agents.
David BurnsClinical Prevention Research Branchburnsda@niaid.nih.gov301-435-8896
Development of formulation strategies to deliver antiretrovirals to specific target cells or tissues.
Development of sustained release formulations to be delivered by oral, injectable, implantable, or transdermal routes of administration for treatment of HIV infection.
Steve TurkDrug Development and Clinical Sciences Branchsturk@niaid.nih.gov301-435-3771
Development of novel and improved assays for the determination of HIV incidence.
These diagnostic assays should identify HIV infection before seroconversion, be based on B and non-B subtypes, andinclude the development, incorporation, and validation of process controls.
Usha SharmaClinical Prevention Researchusharma@niaid.nih.gov301-451-3441
Development of rapid tests for the detection of ARTs in various human matrices (e.g. blood, urine, hair).
The assay should require minimal operator effort and expertise, and include the development, incorporation, and validation of process controls.
Hao ZhangDrug Development and Clinical Sciences Branchhazhang@niaid.nih.gov301.451.2191
back to top
Last Updated May 01, 2014
Last Reviewed May 01, 2014